Literature DB >> 1645777

Identification of lentivirus tat functional domains through generation of equine infectious anemia virus/human immunodeficiency virus type 1 tat gene chimeras.

R Carroll1, L Martarano, D Derse.   

Abstract

The structural regions that comprise the functional domains of lentivirus Tat proteins were examined. Chimeric tat genes and chimeric viral promoters were constructed between the distantly related human immunodeficiency virus type 1 (HIV-1) and equine infectious anemia virus (EIAV). These exchange experiments revealed that the EIAV Tat-responsive element recognition domain is formed by two distinct structural regions. Activation domains of both HIV-1 and EIAV Tat contain a conserved core element, but at least HIV-1 Tat requires the presence of additional structural regions. The interchangeable nature of Tat activation domains suggests that these domains act through a common or ubiquitous cellular transcription factor.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1645777      PMCID: PMC241330     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  63 in total

1.  Specific binding of a HeLa cell nuclear protein to RNA sequences in the human immunodeficiency virus transactivating region.

Authors:  R Gaynor; E Soultanakis; M Kuwabara; J Garcia; D S Sigman
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

2.  Activity of synthetic peptides from the Tat protein of human immunodeficiency virus type 1.

Authors:  A D Frankel; S Biancalana; D Hudson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

3.  Mutational analysis of the conserved basic domain of human immunodeficiency virus tat protein.

Authors:  J Hauber; M H Malim; B R Cullen
Journal:  J Virol       Date:  1989-03       Impact factor: 5.103

4.  Tat trans-activates the human immunodeficiency virus through a nascent RNA target.

Authors:  B Berkhout; R H Silverman; K T Jeang
Journal:  Cell       Date:  1989-10-20       Impact factor: 41.582

5.  Efficient site-directed in vitro mutagenesis using phagemid vectors.

Authors:  J A McClary; F Witney; J Geisselsoder
Journal:  Biotechniques       Date:  1989-03       Impact factor: 1.993

6.  Human immunodeficiency virus 1 tat protein binds trans-activation-responsive region (TAR) RNA in vitro.

Authors:  C Dingwall; I Ernberg; M J Gait; S M Green; S Heaphy; J Karn; A D Lowe; M Singh; M A Skinner; R Valerio
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

7.  trans activation of human immunodeficiency virus type 1 is sequence specific for both the single-stranded bulge and loop of the trans-acting-responsive hairpin: a quantitative analysis.

Authors:  B Berkhout; K T Jeang
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

8.  Multiple functional domains of Tat, the trans-activator of HIV-1, defined by mutational analysis.

Authors:  M Kuppuswamy; T Subramanian; A Srinivasan; G Chinnadurai
Journal:  Nucleic Acids Res       Date:  1989-05-11       Impact factor: 16.971

9.  Analysis of regulatory elements of the equine infectious anemia virus and caprine arthritis-encephalitis virus long terminal repeats.

Authors:  L Sherman; A Yaniv; H Lichtman-Pleban; S R Tronick; A Gazit
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

10.  A region of basic amino-acid cluster in HIV-1 Tat protein is essential for trans-acting activity and nucleolar localization.

Authors:  S Endo; S Kubota; H Siomi; A Adachi; S Oroszlan; M Maki; M Hatanaka
Journal:  Virus Genes       Date:  1989-11       Impact factor: 2.332

View more
  37 in total

1.  Molecular dynamics simulations on HIV-1 Tat.

Authors:  Sergio Pantano; Mudit Tyagi; Mauro Giacca; Paolo Carloni
Journal:  Eur Biophys J       Date:  2003-11-08       Impact factor: 1.733

Review 2.  Mechanism of action of regulatory proteins encoded by complex retroviruses.

Authors:  B R Cullen
Journal:  Microbiol Rev       Date:  1992-09

3.  Functional comparison of the basic domains of the Tat proteins of human immunodeficiency virus types 1 and 2 in trans activation.

Authors:  B Elangovan; T Subramanian; G Chinnadurai
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

4.  Genetic characterization of simian immunodeficiency virus isolated from an African mandrill.

Authors:  H Sakai; J Sakuragi; S Sakuragi; R Shibata; M Hayami; A Ishimoto; A Adachi
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

5.  Mutational analysis of the equine infectious anemia virus Tat-responsive element.

Authors:  M Carvalho; D Derse
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

6.  Inhibition of human immunodeficiency virus type 1 and type 2 Tat function by transdominant Tat protein localized to both the nucleus and cytoplasm.

Authors:  M J Orsini; C M Debouck
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

7.  Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells.

Authors:  Z Dong; M J Birrer; R G Watts; L M Matrisian; N H Colburn
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-18       Impact factor: 11.205

8.  Molecular cloning and characterization of a cellular protein that interacts with the human immunodeficiency virus type 1 Tat transactivator and encodes a strong transcriptional activation domain.

Authors:  L Yu; Z Zhang; P M Loewenstein; K Desai; Q Tang; D Mao; J S Symington; M Green
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

9.  Equine infectious anemia virus resists the antiretroviral activity of equine APOBEC3 proteins through a packaging-independent mechanism.

Authors:  Hal P Bogerd; Rebecca L Tallmadge; J Lindsay Oaks; Susan Carpenter; Bryan R Cullen
Journal:  J Virol       Date:  2008-09-25       Impact factor: 5.103

10.  Inhibitory activity of the equine infectious anemia virus major 5' splice site in the absence of Rev.

Authors:  W Tan; M Schalling; C Zhao; M Luukkonen; M Nilsson; E M Fenyö; G N Pavlakis; S Schwartz
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.